

A diagnostic or prognostic assay is disclosed for a disease or condition characterized by abnormal methylation of cytosine at one or more sites within the glutathione-S-transferase (GST) P1 gene and/or its regulatory flanking sequences (e.g., prostate cancer and liver cancer). The assay comprises:

- (i) isolating DNA from said subject, and
- (ii) determining (e.g., by selective PCR amplification) the presence of abnormal methylation of cytosine at one or more sites within the GST-P1 gene and/or its regulatory flanking sequences.